Dermatology Xagena

Xagena Mappa
Xagena Newsletter
Xagena Salute

Search results for "Guselkumab"

ECLIPSE trial has demonstrated that Guselkumab ( Tremfya ) was superior to Secukinumab ( Cosentyx ) in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at wee ...

Ixekizumab ( Taltz ) met the primary and all major secondary endpoints up to week 12 in the phase 4 IXORA-R study, which evaluated the efficacy and safety of Ixekizumab versus Guselkumab ( Tremfya ) i ...